Pipeline
Callisto Pharmaceuticals develops novel therapeutics for gastrointestinal disease and cancer. At present we have three products in development:
- Our oral Guanylate Cyclase C receptor agonist, SP-304, is in late pre-clinical development for chronic constipation and constipation predominant irritable bowel syndrome. SP-304 is one of only two drugs in a new class of highly efficacious compounds for these very large and underserved markets.
- Atiprimod is an orally available small molecule drug that displays a multiplicity of anti-cancer mechanistic activities. The drug is presently in Phase II development for advanced carcinoid cancer and has potential in several other cancers, including liver and colon as well as mantle cell lymphoma.
- L-Annamycin is a liposome nanoparticle formulation of a second generation anthracycline. It has been developed to address shortcomings with the current generation anthracycline drugs to treat relapsed acute leukemia patients. L-Annamycin has the potential to work against anthracycline-resistant tumors and is expected to have reduced cardiotoxicity. The compound is currently in Phase I/IIa trials for adult and children with relapsed or refractory acute leukemia.
